The impact of protein on Caco-2 permeability of low mass balance compounds for absorption projection and efflux substrate identification

Journal of Pharmaceutical and Biomedical Analysis

Volumn 51, Issue 5, 2010, Pages 1069-1077

  Liu, Tongtong ^a   Chang, Lee Jah ^b   Uss, Annette ^a   Chu, Inhou ^a   Morrison, Richard A ^a   Wang, Lydia ^a   Prelusky, Dan ^a   Cheng, Kuo Chi ^a   Li, Cheng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Absorption prediction; Caco 2 cells; Efflux substrate; Low mass balance; Protein effect

Indexed keywords

BOVINE SERUM ALBUMIN; BREAST CANCER RESISTANCE PROTEIN; CHEMICAL COMPOUND; GLYCOPROTEIN P; PROTEIN;

ABSORPTION; ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CELL MEMBRANE TRANSPORT; CELL STRAIN CACO 2; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOPHILICITY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL ASSAY; BIOLOGICAL TRANSPORT; BUFFERS; CACO-2 CELLS; CATTLE; DIFFUSION; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN, BOVINE;

EID: 72749094660     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.12.006     Document Type: Article

References (23)

1. Li C., Liu T., Broske L., Brisson J.M., Uss A.S., Njoroge F.G., Morrison R.A., and Cheng K.C. Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans. Biochem. Pharmacol. 76 (2008) 1757-1764
2. Grass G.M., and Sinko P.J. Physiologically-based pharmacokinetic simulation modeling. Adv. Drug Deliv. Rev. 54 (2002) 433-451 (Review)
3. Artursson P., and Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175 (1991) 880-885
4. Walter E., Janich S., Roessler B.J., Hilfinger J.M., and Amidon G.L. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J. Pharm. Sci. 85 (1996) 1070-1076
5. Cromwell M.E.W., Shahrokh Z., Villagran J., Nguyen T.N., Wellton M., Nguyen T.H., and Mrsny R.J. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J. Pharm. Sci. 85 (1996) 165-169
6. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, August 2000.
7. Collett A., Tanianis-Hughes J., Hallifax D., and Warhurst G. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm. Res. 21 (2004) 819-826
8. Liu X., Chen C., and Smith B.J. Progress in brain penetration evaluation in drug discovery and development. J. Pharmacol. Exp. Ther. 325 (2008) 349-356
9. Urquhart B.L., Ware J.A., Tirona R.G., Ho R.H., Leake B.F., Schwarz U.I., Zaher H., Palandra J., Gregor J.C., Dresser G.K., and Kim R.B. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet. Genomics 18 (2008) 439-448
10. Nicolazzo J.A., and Katneni K. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). Curr. Top. Med. Chem. 9 (2009) 130-147
11. Suzuki H., and Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci. 12 (2000) 3-12
12. Wacher V.J., Salphati L., and Benet L.Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46 (2001) 89-102
13. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry, Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling, Draft Guidance, September 2006.
14. Fung E.N., Chu I., Li C., Liu T., Soares A., Morrison R., and Nomeir A.A. Higher-throughput screening for Caco-2 permeability utilizing a multiple sprayer liquid chromatography/tandem mass spectrometry system. Rapid Commun. Mass Spectrom. 17 (2003) 2147-2152
15. Li C., Wainhaus S., Uss A.S., and Cheng K.-C. High-throughput screening using Caco-2 and PAMPA systems. In: Ehrhardt C., and Kim K.-J. (Eds). Drug Absorption Studies, In Situ, In Vitro and In Silico Models Preclinical Biopharmaceutics (2008), AAPS Press 418-429
16. Fossati L., Dechaume R., Hardillier E., Chevillon D., Prevost C., Bolze S., and Maubon N. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs. Int. J. Pharm. 360 (2008) 148-155
17. Chiou W.L., and Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. 15 (1998) 1792-1795
18. Korfmacher W.A., Cox K.A., Ng K.J., Veals J., Hsieh Y., Wainhaus S., Broske L., Prelusky D., Nomeir A.A., and White R.E. Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. Rapid Commun. Mass Spectrom. 15 (2001) 335-340
19. Ingels F.M., and Augustijns P.F. Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2. J. Pharm. Sci. 92 (2003) 1545-1558 (Review)
20. Krishna G., Chen K., Lin C., and Nomeir A.A. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int. J. Pharm. 222 (2001) 77-89
21. Saha P., and Kou J.H. Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. Eu. J. Pharm. Biopharm. 54 (2002) 319-324
22. Heimbach T., Oh D.M., Li L.Y., Forsberg M., Savolainen J., Leppanen J., Matsunaga Y., Flynn G., and Fleisher D. Absorption rate limit considerations for oral phosphate prodrugs. Pharm. Res. 20 (2003) 848-856
23. Lakeram M., Lockley D.J., Pendlington R., and Forbes B. Optimisation of the Caco-2 permeability assay using experimental design methodology. Pharm. Res. 25 (2008) 1544-1551